

# STANDARD MEDICARE PART B MANAGEMENT

## ULTOMIRIS (ravulizumab)

### POLICY

#### I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

##### FDA-Approved Indication

1. Paroxysmal nocturnal hemoglobinuria (PNH).
2. Atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA).

##### *Limitations of Use:*

*Ultomiris is not indicated for the treatment of patients with Shiga toxin E. coli related hemolytic uremic syndrome (STEC-HUS).*

All other indications will be assessed on an individual basis. Submissions for indications other than those enumerated in this policy should be accompanied by supporting evidence from Medicare approved compendia.

#### II. CRITERIA FOR INITIAL APPROVAL

##### **A. Paroxysmal Nocturnal Hemoglobinuria (PNH)**

Authorization of 12 months may be granted for treatment of paroxysmal nocturnal hemoglobinuria (PNH).

##### **B. Atypical hemolytic uremic syndrome (aHUS)**

Authorization of 12 months may be granted for treatment of atypical hemolytic uremic syndrome (aHUS) that is not caused by Shiga toxin.

#### III. CONTINUATION OF THERAPY

All members (including new members) requesting authorization for continuation of therapy must be currently receiving therapy with the requested agent.

Authorization for 12 months may be granted when all of the following criteria are met:

1. The member is currently receiving therapy with Ultomiris
2. Ultomiris is being used to treat an indication enumerated in Section II
3. The member is receiving benefit from therapy.

#### IV. REFERENCES

1. Ultomiris [package insert]. Boston, MA: Alexion Pharmaceuticals, Inc.; October 2020.